Vertex Pharmaceuticals Incorporated (VRTX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
94.51-1.29 (-1.35%)
At close: 4:00 PM EDT
People also watch:
ALXNREGNBMRNBIIBINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open95.98
Prev Close95.80
Bid92.02 x 100
Ask99.11 x 400
Day's Range94.04 - 96.16
52wk Range75.90 - 136.97
1y Target EstN/A
Market Cap23.42B
P/E Ratio (ttm)-83.34
Beta1.54
Volume614,716
Avg Vol (3m)1,367,667
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Zacks14 hours ago

    Zacks.com featured highlights: Covanta Holding, ZELTIQ Aesthetics, Capital Senior Living, Live Nation Entertainment and Vertex Pharmaceuticals

    Zacks.com featured highlights: Covanta Holding, ZELTIQ Aesthetics, Capital Senior Living, Live Nation Entertainment and Vertex Pharmaceuticals

  • Barrons.com7 days ago

    Biotech Stocks: Oops, She Did It Again

    Yesterday, biotech stocks--including BioMarin Pharmaceutical (BMRN), Tesaro (TSRO), Vertex Pharmaceuticals (VRTX) and Celgene (CELG)--got pounded after Hillary Clinton tweeted that there was "no justification" for EpiPen price hikes, echoing what happened back in September 2015. RBC's Michael Yee and team consider the implications: The SPDR S&P Biotech index was down -4.3% today (vs SPX down -0.5%) and was one of the sharpest daily moves down in 8 weeks (i.e., Brexit) - but importantly, is after an already large +25% move since the Brexit bottom. Importantly, the sharp pullback was due mostly in our view to investor fear of more political risk around drug pricing concerns and potential changes in the future after Hillary Clinton tweeted "EpiPens can be the difference between life and death.

  • Why no other drug maker was able to close the Medivation deal
    Nicole Sinclair9 days ago

    Why no other drug maker was able to close the Medivation deal

    On Monday, Medivation (MDVN), which owns Xtandi, confirmed it was being acquired by Pfizer (PFE) for $14 billion. This comes just months after Sanofi (SNY) approached Medivation in a hostile deal, going public with its offer and beginning a process to replace the company’s board. Sanofi lost out on its bid to Pfizer, which was willing to pay up and fold Medivation into its oncology franchise.